Palatin To Seek LeuTech BLA Expedited Review For Appendicitis Detection
This article was originally published in The Gray Sheet
Palatin Technologies is targeting this summer for submission of a biologics license application for its LeuTech infection imaging agent for detecting appendicitis in patients with equivocal or suspected appendicitis. Phase III trials were completed in March.
You may also be interested in...
Mallinckrodt's 500-rep sales force will market the radiolabeled monoclonal antibody imaging agent for infection diagnosis, the firms say Aug. 17. St. Louis-based Palatin will receive a $500,000 licensing fee and a $10 mil. milestone payment upon FDA approval, as well as allow a $13 mil. stock purchase by Mallinckrodt. Phase III trials for LeuTech to assist diagnosis of equivocal appendicitis have been completed and the company anticipates filing a biologic license application in September (1"The Gray Sheet" May 3, p. 18)
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.